Form 4: Neurocrine Biosciences Director Exercises Options and Sells Shares Under 10b5-1 Plan

Richard F. Pops, a director at Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 13, 2024, Richard F. Pops, a director of Neurocrine Biosciences Inc., exercised non-qualified stock options to acquire 23,200 shares of common stock at a price of $42.76 per share.
• Simultaneously, Pops sold 23,200 shares of common stock at a weighted average price of $140.3285 per share.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 21, 2023.
• Following these transactions, Pops directly owns 29,512 shares of Neurocrine Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options as a significant component.
• The vesting schedule of the options (12 equal monthly installments) is a typical arrangement.
• The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their stock sales in compliance with SEC regulations.
• Comparing the exercise price and sale price to other biotech companies' executive stock transactions would require further research.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests the transactions were pre-planned and not based on inside information.

Key Dates